2021, Initial Public Offering and Public Trading

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in.

M&A

M&A Mergers and Acquisitions Pharmaceutical Collaboration

Transfer Traps: Considerations for Dual-Class Companies Contemplating M&A Transactions

Cooley M&A

SEPTEMBER 16, 2022

The rise of founder-led, venture capital-backed companies in recent years has coincided with a surge of companies implementing dual-class share structures in connection with their initial public offerings. Voting agreements in public M&A transactions.

M&A

M&A IPO Shares Mergers and Acquisitions

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

JANUARY 25, 2023

billion, a 36% decrease from 2021’s record high of $1.1 As was the case in 2021, software deals remained the strongest performer within the tech sector, representing approximately 90% of tech M&A deals. Deal volumes dropped from $531.13 billion [1] during the first half of 2022 to $189.17 trillion. [2]

M&A

M&A Mergers and Acquisitions Private Equity Mergers

Investment Banking Today

Cooley’s 2022 Life Sciences M&A Year in Review

Transfer Traps: Considerations for Dual-Class Companies Contemplating M&A Transactions

Cooley’s 2022 Tech M&A Year in Review

Stay Connected